CN1391577A - 含金属复合物的药物组合物 - Google Patents

含金属复合物的药物组合物 Download PDF

Info

Publication number
CN1391577A
CN1391577A CN00806748A CN00806748A CN1391577A CN 1391577 A CN1391577 A CN 1391577A CN 00806748 A CN00806748 A CN 00806748A CN 00806748 A CN00806748 A CN 00806748A CN 1391577 A CN1391577 A CN 1391577A
Authority
CN
China
Prior art keywords
bis
ruthenium
iii
methyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00806748A
Other languages
English (en)
Chinese (zh)
Inventor
S·弗里克
M·J·艾布拉姆斯
G·布里杰
R斯基勒
I·贝尔德
B·R·卡梅伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anormed Inc
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of CN1391577A publication Critical patent/CN1391577A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN00806748A 1999-03-19 2000-03-17 含金属复合物的药物组合物 Pending CN1391577A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12516699P 1999-03-19 1999-03-19
US60/125,166 1999-03-19

Publications (1)

Publication Number Publication Date
CN1391577A true CN1391577A (zh) 2003-01-15

Family

ID=22418482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00806748A Pending CN1391577A (zh) 1999-03-19 2000-03-17 含金属复合物的药物组合物

Country Status (15)

Country Link
US (1) US20020049190A1 (https=)
EP (1) EP1163247A1 (https=)
JP (1) JP2004500321A (https=)
KR (1) KR20010112343A (https=)
CN (1) CN1391577A (https=)
AU (1) AU3268500A (https=)
BR (1) BR0011678A (https=)
CA (1) CA2367282A1 (https=)
CZ (1) CZ20013307A3 (https=)
HU (1) HUP0400457A2 (https=)
IL (1) IL145290A0 (https=)
MX (1) MXPA01009410A (https=)
NO (1) NO20014526L (https=)
PL (1) PL356683A1 (https=)
WO (1) WO2000056743A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1916009B (zh) 1999-04-13 2010-12-15 阿诺麦德股份有限公司 制备胺铂配合物的方法
JP4227701B2 (ja) * 1999-05-25 2009-02-18 中部キレスト株式会社 ジエチレントリアミン五酢酸ルテニウム二アンモニウム塩またはその水和物およびその製法
US6489638B2 (en) * 2000-06-23 2002-12-03 Semiconductor Energy Laboratory Co., Ltd. Light emitting device
US6894049B1 (en) 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
NZ534912A (en) * 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
GB2395431A (en) * 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
US7737179B2 (en) * 2003-08-04 2010-06-15 J&J Consumer Companies, Inc. Methods for treatment of dermatological conditions
AU2005210285B2 (en) 2004-02-05 2008-01-24 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
FR2873037B1 (fr) 2004-07-13 2008-04-11 Univ Pasteur Methodes et compositions pour le traitement de cancers
MX2008008104A (es) * 2005-12-21 2008-09-03 Oxford Biosensors Ltd Mediadores redox.
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
EP1995237A4 (en) 2006-03-08 2011-07-06 Kyorin Seiyaku Kk PROCESS FOR PREPARING AN AMINOACETYLPYRROLIDINCARBONITRILE DERIVATIVE AND PRODUCTION PRODUCT THEREOF
ES2444695T3 (es) 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
WO2008038305A2 (en) * 2006-09-26 2008-04-03 Jegannathan Srinivas Therapeutical formulation comprising a thiazolidinedione and a nitric oxide scavenger.
WO2008114857A1 (ja) 2007-03-22 2008-09-25 Kyorin Pharmaceutical Co., Ltd. アミノアセチルピロリジンカルボニトリル誘導体の製造方法
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
DE102010014412A1 (de) 2010-04-08 2012-04-19 Friedrich-Schiller-Universität Jena Verwendung von zweikernigen Eisenkomplexen mit schwefelhaltigen Liganden als pharmakologische Wirkstoffe
DE102010014411A1 (de) 2010-04-08 2011-10-13 Friedrich-Schiller-Universität Jena Kohlenmonoxid und Eisen freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
EP2699242B1 (en) 2011-04-19 2017-11-01 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
DE102012004132A1 (de) 2012-02-29 2013-08-29 Friedrich-Schiller-Universität Jena Kohlenstoffmonoxid freisetzende Materialien und deren Verwendung
DE102014008537A1 (de) 2014-06-04 2015-12-17 Friedrich-Schiller-Universität Jena Wasserlösliche manganbasierte Kohlenstoffmonoxid freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
EP3212610B1 (en) * 2014-10-30 2020-10-28 Katholieke Universiteit Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
CN113429456B (zh) * 2021-06-11 2022-05-31 首都医科大学 多肽衍生物钌类络合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112974A (en) * 1985-01-18 1992-05-12 The Trustees Of Columbia University In The City Of New York Mixed ligand complexes and uses thereof as binding agents to DNA
US4721669A (en) * 1985-01-18 1988-01-26 The Trustees Of Columbia University In The City Of New York Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents
GB9317686D0 (en) * 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions
SE9703396D0 (sv) * 1997-09-19 1997-09-19 Lincoln Binuclear complex

Also Published As

Publication number Publication date
MXPA01009410A (es) 2003-06-06
CZ20013307A3 (cs) 2002-05-15
WO2000056743A1 (en) 2000-09-28
NO20014526L (no) 2001-10-16
NO20014526D0 (no) 2001-09-18
US20020049190A1 (en) 2002-04-25
PL356683A1 (en) 2004-06-28
IL145290A0 (en) 2002-06-30
CA2367282A1 (en) 2000-09-28
EP1163247A1 (en) 2001-12-19
HUP0400457A2 (hu) 2004-05-28
JP2004500321A (ja) 2004-01-08
BR0011678A (pt) 2002-02-26
KR20010112343A (ko) 2001-12-20
AU3268500A (en) 2000-10-09

Similar Documents

Publication Publication Date Title
CN1391577A (zh) 含金属复合物的药物组合物
CN100338077C (zh) 康泼瑞素a－4磷酸前体药物单－和双－有机胺盐,单－和双－氨基酸盐,和单－和双－氨基酸酯盐
CN1224629C (zh) 吡嗪酮蛋白酶抑制剂
CN100339376C (zh) 含氮芳环衍生物
CN1149210C (zh) 凝血酶抑制剂
CN1849122A (zh) Fpt抑制剂与至少两种抗肿瘤药在治疗癌症中的用途
CN1263739C (zh) 羧肽酶u抑制化合物、其制备方法、含有该化合物的药物组合物及其用途
CN1568307A (zh) 作为蛋白酶抑制剂的氨基吡啶基－,氨基胍基－和烷氧基胍基－取代苯基乙酰胺
CN1561207A (zh) 一氧化碳的治疗性释放
CN1098408A (zh) 法呢基蛋白转移酶的杂环抑制剂
CN101077875A (zh) 硼酸酯和硼酸化合物,其合成和应用
CN1341590A (zh) 蛋白酶抑制剂
CN1711089A (zh) 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药
CN1630517A (zh) 包含含氮化合物的具有cxcr4拮抗作用的药物
CN1443173A (zh) 作为TAFIa抑制剂的取代的咪唑
CN1520408A (zh) 哌嗪化合物
CN1460101A (zh) 抑制因子Xa活性的新化合物
CN115850264A (zh) 新型protac化合物及其在抗癌药物中的应用
CN1320123A (zh) 二取代马来酰亚胺化合物及其医药用途
CN1258276A (zh) 细胞增生抑制剂氰基胍
CN1990475A (zh) 取代苯并异硒唑酮类化合物及其用途
CN115894439A (zh) 一种靶向降解gpx4的protac嵌合体及其制备方法和应用
CN1620291A (zh) 作为tafia抑制剂的3－(咪唑基)－2－烷氧基丙酸
CN1599717A (zh) 具有稠环基团的环二胺化合物
CN1741797A (zh) 抑制蛋白质和酶活性的具有配位的双(二苯基膦)二茂铁配体的环钯化合物和相关的疾病和失调的治疗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication